Deltex Medical Group PLC TrueVueTM Loops display launched on CardioQ-ODM+
May 09 2018 - 2:01AM
RNS Non-Regulatory
TIDMDEMG
Deltex Medical Group PLC
09 May 2018
9 May 2018
Deltex Medical Group plc
("Deltex Medical", "Deltex" or the "Company")
TrueVue(TM) Loops display launched on CardioQ-ODM+ platform
Unique combination of flow and pressure broadens clinical
applications
Deltex Medical Group plc (AIM: DEMG), the global leader in
Oesophageal Doppler Monitoring ("ODM"), today announces the launch
of the TrueVue(TM) Loops display software on its CardioQ-ODM+
haemodynamic monitoring platform.
The TrueVue(TM) Loops software is being released globally and is
initially available in English, US English, French, Spanish, German
and Swedish versions. It is available for customers to purchase as
a software licence upgrade to their CardioQ-ODM+ monitor
platforms.
The TrueVue(TM) Loops display gives users a simultaneous display
of a patient's aortic blood flow velocity and aortic blood
pressure. The aortic blood flow velocity is taken directly from the
TrueVue(TM) Doppler probe and the blood pressure from a continuous
blood pressure device.
The display has been developed by doctors from Lariboisiere
Hospital in Paris. Their research has focused on using TrueVue(TM)
Loops to identify the effects of administering vaso-active drugs
and to guide their safe administration. The Company is recruiting
other clinical experts to join a collaborarative research effort to
look at this and other potential clinical applications.
Ewan Phillips, Deltex Medical's Chief Executive, commented:
"Release of the TrueVue(TM) Loops is an exciting development for
the Company. By giving doctors, for the first time ever, a complete
and continuous picture of a patient's cenrtral haemodynamic status
the Loops should take the science of haemodynamics forward in both
intensive and peri-operative care. The initial focus on vaso-active
drugs offers the possibility of Deltex building a strong
competitive advantage in this area to match its existing strength
in fluid management."
For further information, please contact:-
Deltex Medical Group 01243 774 837
plc investorinfo@deltexmedical.com
Nigel Keen, Chairman
Ewan Phillips, Chief
Executive
Jonathan Shaw, Group
Finance Director
Nominated Adviser &
Broker
Arden Partners plc 020 7614 5900
Chris Hardie
Ciaran Walsh
Joint Broker
Turner Pope Investments 0203 621 4120
(TPI) Ltd info@turnerpope.com
Andy Thacker
Financial Public Relations
IFC Advisory Ltd 0203 934 6630
Tim Metcalfe
Graham Herring
Heather Armstrong
Notes for Editors
Deltex Medical manufactures and markets haemodynamic monitoring
technologies. Deltex Medical's proprietary ODM is the only
technology to measure blood flow in the central circulation in real
time. Minimally invasive, easy to set up and quick to focus, the
technology generates a low-frequency ultrasound signal, which is
highly sensitive to changes in flow and measures them immediately.
Deltex has been the only company in the enhanced haemodynamic space
to build a robust and credible evidence base proving the clinical
and economic benefits of its core technology, ODM which is proven
to reduce complications suffered by patients after surgery and save
hospitals the costs of treating those complications.
Deltex Medical's CardioQ-ODM+ platform also now provides
clinicians with two further advanced haemodynamic monitoring
technologies. High Definition Impedance Cardiography is an entirely
non-invasive monitoring technology which creates an electrical
field across the chest and measures the disruption to this field
when the heart pumps blood. Pulse Pressure Waveform Analysis uses
peripheral blood pressure signal analysis to give doctors
information on changes in the circulation and is particularly
suited to monitoring lower risk or haemodynamically stable
patients.
Company goal
Haemodynamic management is now becoming widely accepted as an
important major new medical modality. Consequently, the Company's
focus is on maximising value from the opportunities presented as
enhanced haemodynamic management is adopted into routine clinical
practice around the world. The Company aims to provide clinicians
with a single platform, a 'haemodynamic workstation', which offers
them a range of technologies from simple to sophisticated to be
deployed according to the patient's condition and skill and
expertise of the user. Doing this will enable the Company to
partner healthcare providers to support modern haemodynamic
management across the whole hospital.
The Company is currently in the implementation phase of
achieving this goal in a number of territories worldwide, operating
directly in the UK, USA, Spain and Canada and through distribution
arrangements in a further 30 countries.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRADGGDULGGBGII
(END) Dow Jones Newswires
May 09, 2018 02:01 ET (06:01 GMT)
Deltex Medical (LSE:DEMG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Deltex Medical (LSE:DEMG)
Historical Stock Chart
From Apr 2023 to Apr 2024